Listing of the STXHLT ETF and the Scheme Referencing the Stoxx Global Breakthrough Healthcare Index
SATRIX COLLECTIVE INVESTMENT SCHEME
SATRIX HEALTHCARE INNOVATION FEEDER ETF
JSE Code: STXHLT
ISIN: ZAE000310496
("Satrix Healthcare Innovation" or the "Portfolio")
A portfolio in the Satrix Collective Investment Scheme, registered
as such in terms of the Collective Investment Schemes Control Act,
45 of 2002.
LISTING OF THE SATRIX HEALTHCARE INNOVATION FEEDER ETF AND THE
SCHEME REFERENCING THE STOXX GLOBAL BREAKTHROUGH HEALTHCARE INDEX ON
THE MAIN BOARD OF THE JSE LIMITED (“JSE”) IN THE EXCHANGE TRADED
FUND SECTOR.
This announcement is issued for information purposes only relating
to the listing of the portfolio on the JSE.
1. Introduction
Satrix Healthcare Innovation participatory interests provide the
investors exposure to companies that are focused on innovation
within global healthcare services, across both developed and
emerging markets.
2. Listing approval
Approval for the listing of the participatory interest in the
portfolio was granted by the JSE on 05 May 2022.
3. Summary of the offer
3.1. Issuer
Satrix Healthcare Innovation, a portfolio in the Satrix
Collective Investment Scheme in Securities, registered in
terms of the Collective Investment Schemes Control Act, No 45
of 2002.
3.2. ISIN: ZAE000310496
3.3. Share code: STXHLT
3.4. Long name: Satrix Healthcare Innovation Feeder ETF
3.5. Abbreviated name: SATRIXHLT
3.6. Index
Launched in June 2016, the STOXX Global breakthrough
Healthcare Index belongs to a defined set of developed and
emerging countries, that derive more than 50% of their most
recent total annual revenue from sectors linked to the
breakthrough healthcare trend are highlighted as potential
index components. The index excludes companies that are not
compliant with the Sustainalytics Global Standards Screening
assessment or are involved in Controversial Weapons and other
controversial activities. Moreover, companies that display
high ESG Controversy Ratings are also excluded. The index
constituents are weighted by the security free-float adjusted
market capitalization calculated based on the Foreign
Inclusion Factor (FIF) and subject to Foreign Ownership Limits
(FOLs).
3.7. Distribution or accounting period
The underlying fund reinvests the income from the constituents
in the index and therefore does not distribute.
3.8. The ramp up period
It is the period during which the manager will procure the
acquisition of baskets with the cash proceeds from the initial
offer and will be announced at the close of the offer.
4. Salient dates and times
4.1. Opening date of the initial offer at 09:00 on Wednesday, 04
May 2022
4.2. Closing date of the initial offer at 12:00 on Tuesday, 17 May
2022
4.3. Ramp up period in respect of cash subscriptions commences on
Wednesday, 18 May 2022
4.4. Settlement of Letters of allocation on Thursday, 19 May 2022
4.5. Publication of announcement on SENS as to the results of the
initial offer on Friday, 20 May 2022
4.6. Publication of conversion ratio on Monday, 23 May 2022
4.7 Ramp up period in respect of in specie subscriptions,
Wednesday, 25 May 2022
4.8. Listing date at 9:00 on Thursday, 26 May 2022
* One letter of allocation (“LA”) will be issued for every Rand
subscription against a subscriber’s CSDP or broker account
being debited with the Rand amount. Once the baskets of Index
constituents have been acquired, STRATE will convert the LAs
to Satrix securities in the CSDP accounts in terms of the
conversion ratios that will be published on SENS.
5. Copies of the supplement to the programme memorandum
A supplement to the programme memorandum detailing this offer is
available on the website of the Satrix Collective Investment Scheme
on www.satrix.co.za
05 May 2022
Satrix Managers (RF) Pty Limited
JSE Sponsor
Vunani
Date: 05-05-2022 01:25:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.